
|Articles|November 2, 2012
Similar bleeding rates seen with two anticoagulants
Bleeding rates associated with new use of dabigatran (Pradaxa, Boehringer Ingelheim) do not appear to be higher than bleeding rates associated with new use of warfarin, according to an FDA safety review of post-market reports of serious bleeding events.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
2
Executive Order Calls for Realignment of Childhood Vaccines
3
Q&A: Pharmacists Can Address ADA Standards Across All Settings
4
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
5





























































